Ernexa Therapeutics financials
$3.16−8.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0K | $487.0K | $47.0K | $47.0K | $17.0K | $51.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0K | $547.0K | -$48.0K | -$14.0K | -$49.0K | -$69.0K |
| Gross margin | — | — | — | — | — | — | 100.0% | 112.3% | −102.1% | −29.8% | −288.2% | −135.3% |
| Operating income | -$4.1M | -$5.6M | -$2.1M | -$2.0M | -$2.5M | -$2.7M | -$2.7M | -$2.3M | -$4.9M | -$5.8M | -$5.8M | -$5.5M |
| Net income | -$4.0M | -$5.5M | -$1.5M | -$1.2M | -$3.1M | -$8.2M | -$5.8M | -$26.6M | -$5.5M | -$6.6M | -$6.2M | -$5.6M |
| Net margin | — | — | — | — | — | — | −576700.0% | −5462.8% | −11780.9% | −14142.6% | −36241.2% | −10962.7% |
| Diluted EPS | $-3.40 | $-6.95 | $-2.27 | $-3.75 | $-15.19 | $-57.76 | $-44.63 | $-1842.50 | $-383.50 | $-461.25 | $-426.58 | $-386.25 |
| EBITDA | -$4.1M | -$3.5M | -$1.9M | -$2.0M | -$2.5M | -$2.7M | -$1.2M | -$2.2M | -$4.9M | -$5.7M | -$5.7M | -$5.5M |
| Operating cash flow | -$4.2M | -$2.3M | -$1.1M | -$1.3M | -$2.5M | -$2.1M | -$3.5M | -$6.3M | -$2.3M | -$3.7M | -$4.7M | -$5.8M |
| Free cash flow | -$4.2M | -$2.3M | -$1.2M | -$1.3M | -$2.5M | -$2.1M | -$3.5M | -$6.3M | -$2.5M | -$3.8M | -$4.7M | -$5.8M |
| Diluted shares | 1.2M | 0.8M | 0.7M | 0.3M | 0.2M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.0M | $9.2M | $1.9M | $3.0M | $4.3M | $1.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.3M |
| Total assets | $6.3M | $10.5M | $5.8M | $6.2M | $7.6M | $5.1M |
| Total liabilities | $3.1M | $3.7M | $3.4M | $2.6M | $3.1M | $11.0M |
| Shareholders' equity | $3.2M | $6.9M | $2.4M | $3.6M | $4.4M | -$6.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology